[go: up one dir, main page]

WO2002072003A3 - Use of steroid derivatives for the treatment of a benighn and/or malignant tumour - Google Patents

Use of steroid derivatives for the treatment of a benighn and/or malignant tumour Download PDF

Info

Publication number
WO2002072003A3
WO2002072003A3 PCT/SE2002/000443 SE0200443W WO02072003A3 WO 2002072003 A3 WO2002072003 A3 WO 2002072003A3 SE 0200443 W SE0200443 W SE 0200443W WO 02072003 A3 WO02072003 A3 WO 02072003A3
Authority
WO
WIPO (PCT)
Prior art keywords
androstane
medicament
treatment
derivatives
malignant tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2002/000443
Other languages
French (fr)
Other versions
WO2002072003A2 (en
Inventor
Tomas Hagstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002440973A priority Critical patent/CA2440973A1/en
Priority to EP02704017A priority patent/EP1379542A2/en
Priority to AU2002237613A priority patent/AU2002237613B2/en
Priority to JP2002570963A priority patent/JP2004524325A/en
Publication of WO2002072003A2 publication Critical patent/WO2002072003A2/en
Publication of WO2002072003A3 publication Critical patent/WO2002072003A3/en
Priority to US10/658,125 priority patent/US20050192262A1/en
Anticipated expiration legal-status Critical
Priority to US11/609,643 priority patent/US20070111973A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0014—Androstane derivatives substituted in position 17 alfa, not substituted in position 17 beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are Δ-5-androstene-17α-ol, androstane-17α-ol-pregnane-17α-ol or pregnane-17α-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3ß,17α-diol or androstane-3ßα-diol, an enzyme and a sulfotransferase to provide 5-androstene-17α-ol-3ß-sulfate or corresponding androstane derivative (17α-AEDS or 17-AADS); and mixing the 17α-AEDS or 17α-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to perox-isome proliferator-activated receptor-η (PPARη) is produced.
PCT/SE2002/000443 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour Ceased WO2002072003A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002440973A CA2440973A1 (en) 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
EP02704017A EP1379542A2 (en) 2001-03-13 2002-03-11 Treatment of tumours
AU2002237613A AU2002237613B2 (en) 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
JP2002570963A JP2004524325A (en) 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of benign and / or malignant tumors
US10/658,125 US20050192262A1 (en) 2001-03-13 2003-09-09 Treatment of tumours
US11/609,643 US20070111973A1 (en) 2001-03-13 2006-12-12 Treatment of tumours

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100857-2 2001-03-13
SE0100857A SE0100857D0 (en) 2001-03-13 2001-03-13 Treatment of tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/658,125 Continuation US20050192262A1 (en) 2001-03-13 2003-09-09 Treatment of tumours

Publications (2)

Publication Number Publication Date
WO2002072003A2 WO2002072003A2 (en) 2002-09-19
WO2002072003A3 true WO2002072003A3 (en) 2003-02-20

Family

ID=20283329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2002/000443 Ceased WO2002072003A2 (en) 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour

Country Status (6)

Country Link
EP (1) EP1379542A2 (en)
JP (1) JP2004524325A (en)
AU (1) AU2002237613B2 (en)
CA (1) CA2440973A1 (en)
SE (1) SE0100857D0 (en)
WO (1) WO2002072003A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US7601841B2 (en) 2000-06-28 2009-10-13 Amgen Inc. Quinolinyl and benzothiazolyl modulators
US7626033B2 (en) 1999-06-30 2009-12-01 Amgen Inc. Compounds for the modulation of PPARγ activity

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
ATE411028T1 (en) * 2002-03-21 2008-10-15 Roger M Loria ALPHA-AED AND BETA-AED REGULATION OF NUCLEAR TRANSCRIPTION, GENE REGULATION AND/OR GENE EXPRESSION
CN1964706A (en) 2004-03-17 2007-05-16 拉斯·M·拉森 Preventing retinopathy by inhibiting the visual cycle
GB2421183A (en) * 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
EP2147673A1 (en) * 2006-11-30 2010-01-27 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways
EP2709631B9 (en) 2011-05-20 2017-07-26 INSERM - Institut National de la Santé et de la Recherche Médicale Antagonists of cb1 receptor
CA2892347C (en) 2012-11-28 2019-04-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
WO2023246940A1 (en) * 2022-06-24 2023-12-28 Huang Chi Ying Method of treating a cancer through suppression of growth of cancer stem cells, and downregulation of wnt pathway

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.J. WAXMAN: "Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator", JOURNAL OF ENDOCRINOLOGY, vol. 150, 1996, pages S129 - S147, XP002954541 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7626033B2 (en) 1999-06-30 2009-12-01 Amgen Inc. Compounds for the modulation of PPARγ activity
US7601841B2 (en) 2000-06-28 2009-10-13 Amgen Inc. Quinolinyl and benzothiazolyl modulators
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound

Also Published As

Publication number Publication date
JP2004524325A (en) 2004-08-12
CA2440973A1 (en) 2002-09-19
SE0100857D0 (en) 2001-03-13
AU2002237613B2 (en) 2008-01-03
WO2002072003A2 (en) 2002-09-19
EP1379542A2 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
AU2002316935A1 (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2003070163A3 (en) Prostacyclin derivatives for treating cancer
WO2003068170A3 (en) Enzyme treatment of foodstuffs for celiac sprue
AU2003282234A1 (en) Benzofuran derivates, process for their preparation and intermediates thereof
WO2002072003A3 (en) Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
SI1411932T1 (en) Substituted oxazolidinones for combinational therapy
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
EP1249238A8 (en) Topical pharmaceutical composition comprising bethanechol
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
GB2456976A (en) System and process for producing a low suspended solids solution and uses therefore
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
WO2002007732A3 (en) Use of panaxatriol for stimulation angiogenesis
WO2001015675A3 (en) Use of docetaxel for treating hepatocellular carcinoma
MXPA02009705A (en) New combination of a betablocker and a cholesterol lowering agent.
WO2002087503A3 (en) Compositions and methods for treating colorectal polyps and cancer
AU2003281193A1 (en) Quinazoline derivatives for use in the treatment of cancer
MXPA05001469A (en) Use of fermented wheat germ extract as anti-inflammatory agent.
WO2003089449A3 (en) Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
HK1045987A1 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives
WO2000042987A8 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
WO2001060375A8 (en) Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10658125

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2440973

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002570963

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002704017

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002237613

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002704017

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2002237613

Country of ref document: AU

Date of ref document: 20020311

Kind code of ref document: B